The group will need longer-term data to justify its huge valuation.
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Biogen goes on the offensive against “misinformation” and a media assault, but Roche says patients want clinical benefit, “not imaging”.
Memed claims that its newly CE-marked test can predict Covid-19 severity.
US approvals of high-risk medical devices are way down.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
Awaiting crucial pivotal data, company reckons its plant-generated Covid-19 vaccine can still make a contribution to the pandemic.
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.